August Newsletter: So much to learn about GRIN Disorders…

Share This Post

As parents of children with GRIN Disorders, we crave to learn as much as we can about this rare disease.

Well, on September 13 and 14 there’s a huge opportunity to learn from some of the world’s leading researchers. They’ll be gathering at Emory University in Atlanta.

I’m looking forward to meeting many of you there. But even if you’re unable to be there in person, you can still participate in the conference. 

Please register here for online attendance. A video replay will also be available after the event.

A Big Win for GRIN Research?

Facebook founder Mark Zuckerberg and his wife Priscilla Chan are investing millions into rare disease research.

CureGRIN submitted a letter of interest to the Chan Zuckerberg Initiative for a $450,000 grant to build a patient-led research network for GRIN Disorders.

More than 280 groups submitted letters of interest. Yesterday, CZI reached out to advise that we are part of a smaller subset invited to submit a formal proposal, which is due on October 1. We expect to know by the end of the year if we will be awarded the grant.

Fingers crossed!

Help us Grow

CureGRIN is a new foundation with huge goals. There are so many ways you can help us grow!

Share this newsletter with family members, health care providers, and other GRIN families and encourage them to sign up

Join our Parent Advisory Committee

Choose CureGRIN for your next birthday fundraiser on Facebook

Follow us on Twitter and Facebook

Thanks for all your help!!

Keith

Chief Executive Officer and Head of Science

CureGRIN Foundation

Read more Posts

News

How 2023 brought us closer to treatments and cures

Since our founding in 2019, CureGRIN has been working tirelessly alongside researchers, clinicians and industry to accelerate the path to treatments and cures. There are many promising compounds and genetic treatments, but there are barriers in getting those to clinical trial. Adding ICD-10 codes for these nine genes would remove a significant barrier to clinical trials, by helping us to better understand where our patients are located.

Skip to content